Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UnitedHealth Pursuing Payer/Pharma Collaboration To Evaluate Novel Cancer Treatments

Executive Summary

Four drug manufacturers, three payers and one genetics company are close to launching a pilot that provides pharma companies “an environment where they can supply those early testable drugs to patients anywhere with the right set of complex system biology,” UnitedHealthcare Senior VP Lee Newcomer said.

You may also be interested in...



Lung Cancer “Master Protocol” Eyed As Paradigm-Changing Approach To Drug Development

The biomarker-driven, multi-arm, multi-drug registration trial is expected to get under way in March 2014 with five drugs from different sponsors. With the promise of greater speed and efficiency in patient enrollment and late-stage development, it is being viewed as a potential model for other cancer settings.

The Next Phase In Oncology: FDA’s Pazdur Has New Vision For Drug Development

FDA’s top cancer drug reviewer has taken to the podium to paint a picture of the next phase in cancer drug development, which includes new business models, a return to single-arm trials and a new emphasis on safety.

Cancer Pathways Will Help Inform Drug Performance Measures, Payers Say

Over the last two years, UnitedHealthcare and Aetna have launched cancer pathway programs with the overall goals of standardizing and improving care and lowering cost. Drug therapy is a key focus.

Topics

Related Companies

UsernamePublicRestriction

Register

PS055756

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel